Global Blood Theraps Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLOBAL BLOOD THERAPS, and what generic alternatives to GLOBAL BLOOD THERAPS drugs are available?
GLOBAL BLOOD THERAPS has two approved drugs.
There are ten US patents protecting GLOBAL BLOOD THERAPS drugs.
There are two hundred and fifty-one patent family members on GLOBAL BLOOD THERAPS drugs in forty countries and eleven supplementary protection certificates in ten countries.
Summary for Global Blood Theraps
International Patents: | 251 |
US Patents: | 10 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 2 |
Drugs and US Patents for Global Blood Theraps
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | 11,020,382 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-001 | Nov 25, 2019 | RX | Yes | Yes | 9,248,199 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Global Blood Theraps | OXBRYTA | voxelotor | TABLET;ORAL | 213137-002 | Oct 14, 2022 | RX | Yes | No | 10,017,491 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Global Blood Theraps Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20190041548 | ⤷ Try a Trial |
Slovenia | 3141542 | ⤷ Try a Trial |
Brazil | 112018011272 | ⤷ Try a Trial |
Japan | 6848026 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Global Blood Theraps Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2797416 | 2022C/537 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VOXELOTOR OU UN TAUTOMERE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1622 20220215 |
2797416 | PA2022517 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: VOKSELOTORAS ARBA TAUTOMERAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1622 20220214 |
2797416 | CA 2022 00032 | Denmark | ⤷ Try a Trial | PRODUCT NAME: VOXELOTOR ELLER EN TAUTOMER ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1622 20220215 |
2797416 | LUC00276 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: VOXELOTOR OR A TAUTOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/21/1622 20220215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.